Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-05T12:23:17.684Z Has data issue: false hasContentIssue false

21 - Bupropion

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin, Forfivo XL, Zyban, Contrave

Generic?

• Yes

Class

• Atypical antidepressant

Commonly Prescribed for

(FDA approved in bold)

Major depressive disorder

Seasonal affective disorder (Wellbutrin XL only)

Smoking cessation (Zyban only)

Weight loss (Contrave only)

• Neuropathic pain

• Attention deficit hyperactivity disorder

• Hypoactive sexual desire disorder

• Methamphetamine withdrawal

How the Drug Works

• Both bupropion and its metabolite (hydroxybupropion; half as potent as bupropion) inhibit reuptake of norepinephrine and dopamine

• It also blocks nicotinic acetylcholine receptors

• It does not block reuptake of serotonin nor inhibit monoamine oxidase

How Long Until It Works

• It may take more than 1 month for full effect

If It Works

• Continue to use and monitor for AEs. May continue for 1 year following first depression episode or indefinitely if > 1 episode of depression

If It Doesn't Work

• Increase to highest tolerated dose. Change to another agent or add a second agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Low-dose polytherapy with 2 or more drugs may be better tolerated and more effective than high-dose monotherapy

Tests

• Not available. Monitor blood pressure, seizures, suicidality, and unusual psychiatric behavior

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• By increasing dopamine and norepinephrine concentrations at non-therapeutic responsive receptors throughout the body. Most AEs are dose- and time-dependent

Notable AEs

• ≥ 5%: agitation, dry mouth, constipation, headache, nausea, vomiting, dizziness, hyperhidrosis, tremor, insomnia, blurred vision, tachycardia, confusion, rash, hostility, cardiac arrhythmia, hypertension, auditory disturbance

Life-Threatening or Dangerous AEs

• Worsening of depression and suicidality

• Rare hepatitis

• Rare activation of mania or suicidal ideation

• Rare worsening of coexisting seizure disorders

Weight Gain

• Unusual

Sedation

• Unusual

What to Do About AEs

• For minor AEs, lower dose, titrate slower, or switch to another agent. For serious AEs, lower dose and consider stopping, taper to avoid withdrawal symptoms

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 78 - 81
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Bupropion
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.022
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Bupropion
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.022
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Bupropion
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.022
Available formats
×